Empagliflozin and Dapagliflozin Outcomes in Heart Failure
In this cohort study of patients with HF, dapagliflozin and empagliflozin had similar clinical outcomes in HF management. Further research and clinical trials are necessary to validate these findings and inform clinical decision-making.
Authors
- Hyo-Suk Ahn
- Jung Sun Cho (ORCID: https://orcid.org/0000-0002-0308-0021)
- Hwajung Kim (ORCID: https://orcid.org/0000-0002-8189-8689)
- Seonghyeon Bu (ORCID: https://orcid.org/0000-0003-2754-8116)
- Jeong‐Eun Yi (ORCID: https://orcid.org/0000-0003-2614-6983)
- Seoree Kim (ORCID: https://orcid.org/0000-0001-7461-103X)
- Dong‐Ho Shin (ORCID: https://orcid.org/0000-0002-7874-5542)
- Nay Aung (ORCID: https://orcid.org/0000-0001-5095-1611)
- You Mi Hwang (ORCID: https://orcid.org/0000-0001-8385-6485)
- Dongjae Lee (ORCID: https://orcid.org/0000-0003-3142-102X)
- Dukmoon Chung
- Mi-Hyang Jung
Institutions
- Queen Mary University of London (GB)
- Yonsei University (KR)
- St. Mary's Hospital (US)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
- The Catholic University of Korea Yeouido St. Mary's Hospital (KR)
- The Catholic University of Korea Daejeon St. Mary's Hospital (KR)
- The Catholic University of Korea Bucheon St. Mary's Hospital (KR)
- William Harvey Research Institute (GB)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.46865
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59